Neurologix Completes Procedures in Landmark Phase I Gene Therapy Trial

Neurologix has announced the completion of all neurosurgical gene transfer procedures in its landmark, 12-patient, dose-escalating Phase I clinical trial of gene therapy for Parkinson's disease.

The Neurologix trial is the first in which a virus was injected directly into the brain to transfer a gene to treat Parkinson's disease, the company said. Researchers reported all patients underwent the surgical gene transfer procedure while awake and under only local anesthesia. All patients were discharged from the hospital within 48 hours.

There has been no evidence of any treatment-related adverse effects to date. Patients have now been followed from one to 22 months post procedure.